Tag: Ocugen

Ocugen's full-year 2025 financial results, released on March 4, 2026, underscore a period of intense clinical advancement. The company's pipeline ...

Biotechnology firm Ocugen has completed patient enrollment for the pivotal Phase 3 clinical trial of its lead candidate, OCU400, a ...

Biopharmaceutical firm Ocugen has achieved a significant clinical development goal just two days before its annual financial report. Company leadership ...

Biotechnology firm Ocugen has bolstered its financial position through a recent capital raise, providing crucial resources as it approaches significant ...

Investors are piling into Ocugen, Inc., driving a significant rally in the biotech firm's share price. The upward momentum is ...

Friday's trading activity for Ocugen presented a market conundrum. While the share price itself declined, a surge in bullish options ...

In a decisive move aligning leadership incentives with corporate goals, Ocugen, Inc. has established a substantial performance-based equity award for ...

Shares of clinical-stage biopharmaceutical company Ocugen saw elevated trading activity on Monday, with volume running 72% above the average. This ...

Ocugen's stock closed at $1.38 on Friday, marking a single-day gain of 5.34%. This advance represents the third consecutive trading ...

The biotechnology firm Ocugen enters the new trading week with positive momentum. Following a multi-day advance, investors are assessing whether ...